Subscribe Now Subscribe Today
Science Alert
 
FOLLOW US:     Facebook     Twitter
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2016 | Volume: 12 | Issue: 8 | Page No.: 838-844
DOI: 10.3923/ijp.2016.838.844
Combination Effect Between 2, 4-Di-tert-butylphenol Produced by Streptomyces sp. KB1 TISTR 2304 and Vancomycin Against Methicillin-resistant Staphylococcus aureus (MRSA)
Kittisak Chawawisit, Phuangthip Bhoopong, Worrapong Phupong and Monthon Lertcanawanichakul

Abstract:
Background: The MRSA is multi-drug resistant pathogenic bacteria had become a worldwide concern because its susceptibility to vancomycin was decreasing and also administration of high doses of vancomycin has been used to treat. Thus, the combined strategy of bioactive compounds from microorganisms with currently used antibiotics was interested to solve this problem. Objective: This study aimed to evaluate the combination effect between 2, 4-Di-tert-butylphenol and vancomycin against MRSA. Materials and Methods: The anti-MRSA activity of 2,4-Di-tert-butylphenol and vancomycin was initially performed by the broth microdilution method to determine the Minimum Inhibitory Concentration (MIC) value. The combination effect of them was performed by the checkerboard method to determine the Fractional Inhibitory Concentration (FIC) index value. Results: The MIC values of 2, 4-Di-tert-butylphenol and vancomycin were in the range of 15.63-62.50 and 1.56-3.12 μg mL–1, respectively. Among 10 clinical isolates of MRSA, 5 isolates which showed phenotype as inducible macrolide-lincosamide-streptogramin group B (iMLSB) resistance were inhibited by combining the 15.63 μg mL–1 of 2, 4-Di-tert-butylphenol with 0.39-0.78 μg mL–1 of vancomycin. The FIC index values were in the range of 0.56-0.75 which could conclude as partial synergism. Contrarily, another 5 isolates that showed phenotype as constitutive MLSB (cMLSB) resistance were evaluated as indifferent activity which showed the FIC index values were in the range of 1.0-1.5. Conclusion: The 2, 4-Di-tert-butylphenol should not use to combine with vancomycin for treating the infection of MRSA in group of cMLSB phenotype, but it might use to combine with vancomycin for treatment in group of iMLSB phenotype.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Kittisak Chawawisit, Phuangthip Bhoopong, Worrapong Phupong and Monthon Lertcanawanichakul, 2016. Combination Effect Between 2, 4-Di-tert-butylphenol Produced by Streptomyces sp. KB1 TISTR 2304 and Vancomycin Against Methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Pharmacology, 12: 838-844.

DOI: 10.3923/ijp.2016.838.844

URL: https://scialert.net/abstract/?doi=ijp.2016.838.844

 
COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

       

       

Curve Bottom